Replimune Group, Inc.
NASDAQReplimune Group heads into its September 15 earnings report with a sharp disconnect: short interest is near a one-month high, yet analysts have been upgrading the stock in a cluster rarely seen for a name with this much regulatory overhang. The short-side pressure is real and growing. Short interest has climbed to 34.4% of the free float — up 43% over the past month, with the bulk…
REPL short interest surges 37% in one week to 32.4% of float, highest level since July as stock rallies 18% amid analyst upgrades and BLA resubmission hopes.
Replimune Group heads into its September 15 earnings report with a sharp disconnect: short interest is near a one-month high, yet analysts have been upgrading the stock in a cluster rarely seen for a name with this…
Replimune Group enters its August 18 earnings print with the sharpest bull-bear split in months — short sellers rebuilding aggressively while the analyst community upgrades in near-unison. Short interest has become the…
Snapshot as of 24 Sept 2026
Replimune Group heads into its August 18 earnings print caught between a sharp short-interest build and the most concentrated analyst upgrade cycle the stock has seen in months. The short-side story is the most…
Options traders have turned sharply bearish on REPL just as short sellers begin covering. The divergence is the standout story on Replimune Group right now. The put-call ratio hit 0.71 on July 15. That is 2.47 standard…
REPL heads into its June 4 earnings with one of the most combustible positioning setups in small-cap biotech: a heavily shorted stock that has tripled in a month. The short-side squeeze pressure is genuine. Short…
Replimune Group enters its May 15 earnings report in one of the most electrically charged setups in the biotech space right now: a 43% weekly surge, a third of the float still sold short, and call buyers running the…
Replimune Group heads into its May 15 earnings with nearly a quarter of its free float sold short — a position that has been building quietly since a devastating regulatory setback in April. Short interest commands the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for REPL — free to start on ORTEX.
Sign up for free →Open REPL on ORTEX